These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 33631091)

  • 1. Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management.
    Alcantara M; Mezei MM; Baker SK; Breiner A; Dhawan P; Fiander A; Fine NM; Hahn C; Katzberg HD; Khayambashi S; Massie R; Matte G; Putko B; Siddiqi Z; Delgado D; Bril V
    Can J Neurol Sci; 2022 Jan; 49(1):7-18. PubMed ID: 33631091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.
    Adams D; Ando Y; Beirão JM; Coelho T; Gertz MA; Gillmore JD; Hawkins PN; Lousada I; Suhr OB; Merlini G
    J Neurol; 2021 Jun; 268(6):2109-2122. PubMed ID: 31907599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.
    Carroll A; Dyck PJ; de Carvalho M; Kennerson M; Reilly MM; Kiernan MC; Vucic S
    J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):668-678. PubMed ID: 35256455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L
    Coelho T; Ando Y; Benson MD; Berk JL; Waddington-Cruz M; Dyck PJ; Gillmore JD; Khella SL; Litchy WJ; Obici L; Monteiro C; Tai LJ; Viney NJ; Buchele G; Brambatti M; Jung SW; St L O'Dea L; Tsimikas S; Schneider E; Geary RS; Monia BP; Gertz M
    Neurol Ther; 2021 Jun; 10(1):375-389. PubMed ID: 33638113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.
    Nie T; Heo YA; Shirley M
    Drugs; 2023 Oct; 83(15):1425-1432. PubMed ID: 37728865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.
    Skrahina V; Grittner U; Beetz C; Skripuletz T; Juenemann M; Krämer HH; Hahn K; Rieth A; Schaechinger V; Patten M; Tanislav C; Achenbach S; Assmus B; Knebel F; Gingele S; Skrahin A; Hartkamp J; Förster TM; Roesner S; Pereira C; Rolfs A
    Ann Med; 2021 Dec; 53(1):1787-1796. PubMed ID: 34658264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium.
    De Bleecker JL; Claeys KG; Delstanche S; Van Parys V; Baets J; Tilleux S; Remiche G
    Acta Neurol Belg; 2023 Jun; 123(3):1029-1037. PubMed ID: 36829087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts.
    Karam C; Mauermann ML; Gonzalez-Duarte A; Kaku MC; Ajroud-Driss S; Brannagan TH; Polydefkis M
    Muscle Nerve; 2024 Mar; 69(3):273-287. PubMed ID: 38174864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.
    Gertz MA; Scheinberg M; Waddington-Cruz M; Heitner SB; Karam C; Drachman B; Khella S; Whelan C; Obici L
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):701-711. PubMed ID: 31268366
    [No Abstract]   [Full Text] [Related]  

  • 10. [Gene therapy options for hereditary transthyretin-related amyloidosis].
    Schilling M
    Nervenarzt; 2022 Jun; 93(6):557-565. PubMed ID: 35419654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [de novo hATTR amyloidosis after domino transplantation of a donor's liver: a case report for the use of Patisiran].
    Schmidt M; Yilmaz A; Bietenbeck M; Schilling M; Röcken C; Schmidt HH
    Z Gastroenterol; 2022 Nov; 60(11):1659-1664. PubMed ID: 35533685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropathy Associated with Systemic Amyloidosis.
    Kaku M; Berk JL
    Semin Neurol; 2019 Oct; 39(5):578-588. PubMed ID: 31639841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
    Obici L; Berk JL; González-Duarte A; Coelho T; Gillmore J; Schmidt HH; Schilling M; Yamashita T; Labeyrie C; Brannagan TH; Ajroud-Driss S; Gorevic P; Kristen AV; Franklin J; Chen J; Sweetser MT; Wang JJ; Adams D
    Amyloid; 2020 Sep; 27(3):153-162. PubMed ID: 32131641
    [No Abstract]   [Full Text] [Related]  

  • 14. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.
    Benson MD; Waddington-Cruz M; Berk JL; Polydefkis M; Dyck PJ; Wang AK; Planté-Bordeneuve V; Barroso FA; Merlini G; Obici L; Scheinberg M; Brannagan TH; Litchy WJ; Whelan C; Drachman BM; Adams D; Heitner SB; Conceição I; Schmidt HH; Vita G; Campistol JM; Gamez J; Gorevic PD; Gane E; Shah AM; Solomon SD; Monia BP; Hughes SG; Kwoh TJ; McEvoy BW; Jung SW; Baker BF; Ackermann EJ; Gertz MA; Coelho T
    N Engl J Med; 2018 Jul; 379(1):22-31. PubMed ID: 29972757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7.
    Dyck PJB; González-Duarte A; Obici L; Polydefkis M; Wiesman JF; Antonino I; Litchy WJ; Dyck PJ
    J Neurol Sci; 2019 Oct; 405():116424. PubMed ID: 31445300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system.
    Conceição I
    Clin Auton Res; 2019 Sep; 29(Suppl 1):11-17. PubMed ID: 31399774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ala97Ser transthyretin amyloidosis-associated polyneuropathy, clinical and neurophysiological profiles in a Thai cohort.
    Pasutharnchat N; Taychargumpoo C; Vorasettakarnkij Y; Amornvit J
    BMC Neurol; 2021 May; 21(1):206. PubMed ID: 34022837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry.
    Parker MM; Damrauer SM; Tcheandjieu C; Erbe D; Aldinc E; Hawkins PN; Gillmore JD; Hull LE; Lynch JA; Joseph J; Ticau S; Flynn-Carroll AO; Deaton AM; Ward LD; Assimes TL; Tsao PS; Chang KM; Rader DJ; Fitzgerald K; Vaishnaw AK; Hinkle G; Nioi P
    Sci Rep; 2021 Jun; 11(1):11645. PubMed ID: 34079032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variable Presentation of Hereditary Transthyretin-Mediated Amyloidosis at a Single Center.
    Hussain Y
    J Clin Neuromuscul Dis; 2021 Sep; 23(1):7-17. PubMed ID: 34431796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Gorevic P; Franklin J; Chen J; Sajeev G; Wang JCH; Lin H
    Expert Opin Pharmacother; 2021 Jan; 22(1):121-129. PubMed ID: 32892660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.